[Table/Fig-7]:
Subjects | U1–PP | U6-PP | U1E-Ver | U1A-Ver | U6C-Ver | |||||
---|---|---|---|---|---|---|---|---|---|---|
Pre-Rx | Post-Rx | Pre-Rx | Post-Rx | Pre-Rx | Post-Rx | Pre-Rx | Post-Rx | Pre-Rx | Post-Rx | |
Group A | ||||||||||
1 | 126 | 111 | 86 | 86 | 31 | 30 | 10 | 9 | 26 | 26 |
2 | 122 | 110 | 81 | 81 | 29 | 27 | 6 | 4.5 | 22 | 22 |
3 | 130 | 114 | 92 | 92 | 27 | 29 | 6.7 | 6 | 25 | 25 |
4 | 125 | 129 | 89 | 92 | 29 | 27 | 6.5 | 5 | 27.5 | 26.5 |
5 | 130 | 119 | 85 | 81 | 27 | 29 | 4.7 | 5.5 | 24.5 | 24 |
6 | 118 | 110 | 82 | 85 | 34 | 33 | 8 | 7 | 29.5 | 28.5 |
7 | 114 | 108 | 85 | 84 | 34 | 34 | 11 | 11 | 28 | 28 |
8 | 123 | 111 | 82 | 82 | 29 | 27 | 7 | 5.5 | 23 | 23 |
9 | 126 | 111 | 86 | 86 | 31 | 30 | 10 | 9 | 26 | 26 |
10 | 122 | 110 | 81 | 81 | 29 | 27 | 6 | 4.5 | 22 | 22 |
Group B | ||||||||||
1 | 123 | 117 | 79 | 87 | 31 | 28 | 7.8 | 5 | 25 | 23 |
2 | 127 | 110 | 79 | 85 | 28 | 30 | 5.5 | 5.8 | 24 | 26 |
3 | 125 | 123 | 87 | 90 | 32.5 | 30 | 7.5 | 7.3 | 25 | 27 |
4 | 120 | 128 | 86 | 89 | 32 | 28.5 | 5 | 5 | 26 | 24.5 |
5 | 118 | 109 | 87 | 88 | 30 | 30 | 6 | 6 | 22 | 22 |
6 | 129 | 129 | 89 | 90 | 38 | 27 | 6 | 7 | 23 | 23 |
7 | 120 | 115 | 84 | 88 | 29 | 29 | 6 | 6 | 25 | 25 |
8 | 122 | 116 | 78 | 86 | 31 | 30 | 7 | 5 | 25 | 24 |
9 | 123 | 117 | 79 | 87 | 31 | 28 | 7.8 | 5 | 25 | 23 |
10 | 127 | 110 | 79 | 85 | 28 | 30 | 5.5 | 5.8 | 24 | 26 |